CI

Cigna GroupA

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$335.00

Analysis reference price unavailable

Analysis 2026-05-03 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$315.00

Analysis reference price unavailable

Analysis 2026-05-03 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$255.00

Analysis reference price unavailable

Analysis 2026-05-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

Primary-source support is solid because the April 30 8-K and earnings release clearly confirm a beat-and-raise quarter, and secondary coverage adds consensus-beat framing plus at least one post-print target increase. Even so, sentiment looks mixed rather than euphoric: Reuters-linked and other coverage highlighted PBM profit pressure and the ACA marketplace exit, and the May 1 anchor price of $282.90 sits below some pre-print reference prices in trusted coverage, implying the initial earnings upside did not translate into a clean rerating. Analyst-revision breadth is still incomplete at T+3, and the more relevant comparison set is managed-care and PBM peers such as ELV, UNH, and CVS rather than medtech names, so this remains a cautious post-earnings monitoring memo rather than a high-conviction upgrade.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystPost-Q1 beat-and-raise revision cycleMedium impact

The April 30 earnings release showed Q1 2026 revenue up 5% to $68.5B, adjusted income from operations of $7.79 per share, and full-year adjusted income from operations guidance raised to at least $30.35 per share; Reuters-linked coverage also framed the print as above estimates, and a May 2026 Mizuho note raised its price target to $330 from $325 while maintaining Outperform. [#8-K-2026-04-30]

2026-07-01eventJuly 1 CEO transition to Brian EvankoMedium impact

Cigna announced that David Cordani will retire as CEO effective July 1, 2026 and Brian Evanko will succeed him, with Cordani becoming executive chair; the transition creates a dated governance checkpoint for execution and investor messaging.

2026-07-30catalystSegment mix shift toward specialty growth while PBM pressure stabilizesHigh impact

Evernorth Specialty and Care Services grew adjusted revenue 6% and pre-tax operating income 20%, helped by strong specialty volume and more generic and biosimilar adoption, while Pharmacy Benefit Services revenue rose 11% but pre-tax income fell 28% on lower contributions from large client relationships; sustained improvement depends on specialty growth continuing to offset PBM pressure. [#8-K-2026-04-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology